Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.

about

Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.

Item

http://www.wikidata.org/entity/Q41696217

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Motivators and barriers of tam ...... systematic literature review.

@en

type

Item

label

Motivators and barriers of tam ...... systematic literature review.

@en

prefLabel

Motivators and barriers of tam ...... systematic literature review.

@en

P1476

Motivators and barriers of tam ...... systematic literature review.

@en

P2093

C Julian-Reynier

http://www.w3.org/2001/XMLSchema#string

G Mitchell

http://www.w3.org/2001/XMLSchema#string

J Kirk

http://www.w3.org/2001/XMLSchema#string

M Peate

http://www.w3.org/2001/XMLSchema#string

W K T Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis

Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.

Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.

Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.

P2888

s13053-017-0075-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13053-017-0075-8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bettina Meiser

P577

2017-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091875693

http://www.w3.org/2001/XMLSchema#string

P698

28943990

http://www.w3.org/2001/XMLSchema#string

P932

5607482

http://www.w3.org/2001/XMLSchema#string